Allergy

The findings provide data to help physicians, patients, and caregivers make informed, shared decisions on the management of peanut allergy.

Although a majority of pediatricians are aware of the guidelines, less than one-third of survey respondents report full implementation.

The results further support the overall benefit of epicutaneous immunotherapy.

There is also an association between late onset of spring and an increase in hospital admissions for asthma.

The biologic has now shown significant efficacy in treating 4 different atopic or type 2 inflammatory diseases.

The newest indication for the add-on biologic grants it use in children aged 6-11 years old with moderate to severe, uncontrolled atopic dermatitis.

A look at how the antibody influences the pathology of encephalitis, and how it can be properly assessed and treated.

The IL-17A-targeting biologic has now been indicated for pediatric plaque psoriasis—marking its fourth indication for patients with chronic diseases.

A new summary of recent cow's milk allergy guidelines show conlficting consensus on identifying and caring for infantile allergic symptoms.

Clinical investigator and allergist Jonathan Corren, MD, shares insight on the TSLP inhibitor.

New data shows higher rates of cancer and cardiovascular disease deaths for patients with celiac disease.

New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.

Discussing an editorial in the Journal of Clinical Endocrinology & Metabolism with journal editor in chief Paul Stewart, MD.

What effect may professional athletes receiving asymptomatic tests have on the public perception of the coronavirus?

The three-year study represents the largest long-term kinetic immunotherapy trial.

The label update comes after findings have repeatedly shown an associated risk of neuropsychiatric events.

New data evidences yet another IL-13 targeting biologic for atopic dermatitis.

The FDA announced the switch of the 2 eyedrops, which took place through their RX-to-OTC program.

Nearly one dozen therapies have reached the psoriasis market, and the new standard is at least 90% skin clearance—an achievement previously unmet.

In 2015, a study changed the entire understanding of peanut allergen exposure. Physicians are still trying to understand how to implement it today.

Are current methods and biomarkers viable, or are there better options to uncover?

In months, the US may have its first marketed peanut immunotherapies. How will pediatric patient management change?

An analysis of mepolizumab use shows fewer than 1% of prescribed patients are likely to use biologics concomitantly.

For what other indications, and in what regimens, are investigators assessing the drug class?

Certain diet-based comorbid conditions are more prevalent in food-allergic patients.

At least 1 major food allergy trial in recent years has given allergists incentive to set detailed strategies for their patients.

Could the drug class best serve patients as an adjunctive, a monotherapy, or maybe a prophylaxis for symptoms?

Though research behind preventive measures is lacking, there are common steps that could be taken to reduce pediatric risk.

As new methods of treatment come to the market, allergists need to ensure their patients are fully informed and able to set their own goals for care.

A new survey shows more than 60% of adult patients with peanut allergy do not feel confident in managing their condition, despite taking preventive measures.